Latest news with #YMAB
Business Insider
29-05-2025
- Business
- Business Insider
Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB)
Clear Street analyst William Maughan reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $17.00. The company's shares closed today at $4.62. Confident Investing Starts Here: Maughan covers the Healthcare sector, focusing on stocks such as Y-Mabs Therapeutics, Delcath Systems, and Summit Therapeutics. According to TipRanks, Maughan has an average return of 18.5% and a 49.37% success rate on recommended stocks. In addition to Clear Street, Y-Mabs Therapeutics also received a Buy from H.C. Wainwright's Robert Burns in a report issued on May 19. However, on May 13, Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (NASDAQ: YMAB). Based on Y-Mabs Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.9 million and a GAAP net loss of $5.2 million. In comparison, last year the company earned a revenue of $19.93 million and had a GAAP net loss of $6.63 million Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year. Most recently, in March 2025, Thomas Gad, the CBO of YMAB sold 10,810.00 shares for a total of $56,536.30.
Yahoo
28-05-2025
- Business
- Yahoo
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. The focus of the company's presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28. The company's stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%. While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. The focus of the company's presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28. The company's stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%. While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. The focus of the company's presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28. The company's stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%. While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
28-04-2025
- Health
- Business Insider
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at the 2025 American Association of Cancer Research, AACR, Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled 'Preclinical and translational pharmacokinetic modeling of the self-assembling and disassembling, SADA, bispecific fusion protein CD38-SADA for first-in-human pretargeted radioimmunotherapy' characterizes the plasma concentrations of CD38-SADA in animal models over time and a range of doses. Utilizing in vitro binding kinetic parameters and PK data generated from three studies in mice, the study characterized the concentration- and time-dependent equilibrium between CD38-SADA tetramers and monomers Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
